We’re forming a Community Engagement Council to guide an innovative research study aimed at increasing HPV vaccine knowledge, reducing stigma, and improving vaccine equity among young men who have sex with men (YMSM) across Canada. Together, we’ll co-design an accessible, user-centered digital health literacy tool specifically for YMSM.
This research study aims to further understand and prevent information and communication challenges from influencing vaccine acceptance in the future. The study team will work together with the public and other stakeholders to develop digital messages that help people understand vaccines better and encourage future novel and routine vaccine uptake.
The purpose of this study is to increase the accessibility and uptake of recommended immunizations by exploring solutions to cost-related barriers through community pharmacies for the delivery of recommended but unfunded vaccines until full public funding is available. It is anticipated that results on the acceptability and feasibility of implementing alternative funding models for recommended but unfunded vaccines may be used to test a workable funding model and to inform funding decisions by private and public payers.
We are conducting a study to compare the immune response to those who received a Mpox (formerly known as monkeypox) vaccine (Imvamune®),
a smallpox vaccine (those born between 1948-1975), or no poxvirus vaccine.
This clinical trial is evaluating an investigational vaccine that aims to protect babies from RSV. The trial is being conducted to see whether an investigational vaccine given to pregnant women may potentially help protect their babies during the vulnerable first few months by passing on immunity through the placenta. This process works for vaccines such as whooping cough, tetanus, flu, and COVID-19.
This is a phase 3 study. We are looking to test the safety and effectiveness of mRNA-1403 vaccine for Norovirus.
The purpose of this clinical trial is to evaluate the safety and effectiveness of mRNA-1647 vaccine for Cytomegalovirus (CMV). The use of a safe and effective vaccine may potentially prevent CMV infection. There is currently no approved vaccine to prevent CMV infection.
The main goals of this study are:
– To see if the study vaccine can prevent CMV infection in participants who have not been previously infected with CMV
– To understand the safety (side effects) of the study vaccine
– To see if the study vaccine results in participants making antibodies to CMV
